Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Expects 5 Percent Rise in 2021 Revenues

NEW YORK — HTG Molecular Diagnostics on Thursday posted $8.9 million in preliminary revenues for 2021, a nearly 5 percent increase over the year before.

Analysts, on average, are expecting $8.84 million in revenues for 2021, and HTG generated revenues of $8.5 million in 2020.

HTG said the 2021 revenues include around $1.4 million from its recently launched HTG Transcriptome Panel (HTP), a research-use-only kit designed to measure approximately 20,000 mRNA targets using Illumina's sequencing platforms.

The Tucson, Arizona-based company said it had $21.9 million in cash, cash equivalents, and short-term marketable securities as of Dec. 31.

Full financial results for 2021 are scheduled for release before the company reports its first quarter results in March.

"As we turn the page to 2022, we look forward to continuing our efforts to generate our first dataset for our newly formed HTG Therapeutics business unit, while expecting continued growth in profiling revenue as customers and collaborators complete their initial validation of HTP, evidenced through publications and continued investment in our technology," HTG CEO John Lubniewski said in a statement.

The Scan

Sensor to Spot SARS-CoV-2 Exposure

Yale researchers have developed a sensor that gauges SARS-CoV-2 exposure, according to the New Haven Register.

Watching BA.2

A subtype of the Omicron SARS-CoV-2 variant has been found in a number of countries, the Washington Post says.

Vermont Weighs Genetic Discrimination Bill

VT Digger reports Vermont legislators are considering a bill to bar insurer from denying customers coverage based on genetic information.

PNAS Papers on Convergent Pathogen Effectors, Lineage-Related RNA Mutations, Desiccation-Tolerant Grass

In PNAS this week: convergent evolution of pathogen effectors, algorithm to identify cell lineage features, and more.